Professor Kulish expertise spans through strategic, organizational, and technology topics in Russian and global pharmaceutical and biotechnology industries, as well as innovation in general. During his 20+-year career, Dmitry has managed and led Russian and international teams with emphasis on pharmaceutical innovation, venture development, product development and manufacturing. He served at the top executive positions at prominent Russian pharmas (R-Pharm, Nanolek, Bioprocess-Pharmapark), esteemed MNCs (Fresenius Kabi and Intel Capital), as well as budding biotech start-ups. After completing the corporate career in 2014, Professor Kulish established a consultancy “DrugDevelopment.Ru” that advises pharmaceutical and investment companies on the broad range of strategic and operational issues related to Russian and global pharmaceutical business.
At Skoltech CEI Professor Kulish leads the pharmaceutical practice based on three interdependent activities:
Professor Kulish holds PhD in Biochemistry from Moscow Institute of Molecular Genetics, MBA in Business Strategy from the Wharton School of Business, and MA in Biotechnology from Moscow Institute of Fine Chemical Technology. Dmitry was a Postdoctoral Fellow in Molecular Pharmacology at Harvard University.